Prime Medicine
Michael Reed has a diverse work experience in the field of scientific research. Michael currently holds the position of Scientist II at Prime Medicine, Inc. since February 2023. Previously, they worked as a Scientist at the same company from August 2021 to February 2023. Before joining Prime Medicine, Inc., Michael was a Research Fellow at Biogen from January 2020 to August 2021, where they focused on multiple sclerosis research. Michael also served as a Graduate Student at the Massachusetts Institute of Technology from September 2013 to December 2019, where they conducted neuroimmunological research related to Autism-like behavioral phenotypes. Prior to that, they worked as a Research Technician at Harvard Medical School from May 2012 to September 2013, where they utilized transmission electron microscopy for cortical functional connectivity analysis. Michael began their research career at Johns Hopkins University as a Research Technician from May 2011 to May 2012. Michael's early research experience includes being a Research Student at Northeastern University from June 2009 to May 2011. Overall, Michael Reed has gained extensive expertise and knowledge through their various roles in the scientific research field.
Michael Reed attended Northeastern University from 2007 to 2011, where they earned a Bachelor of Science (B.S.) degree in Behavioral Neuroscience. Following their undergraduate studies, they pursued higher education at the Massachusetts Institute of Technology from 2013 to 2019. During this time, Michael completed a Doctor of Philosophy (PhD) degree in Neuroscience.
This person is not in the org chart
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.